Filing Flows › Regeneron Pharmaceuticals (REGN) › Guidance history
Regeneron Pharmaceuticals (REGN) guidance history: what it guided and what it reported
Regeneron Pharmaceuticals gave guidance in 2 earnings releases on file since Oct 30, 2026.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | $7.0B (Oct 30, 2026) | — | to be reported | — |
Capital expenditures
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $1.1B–$1.1B (Oct 30, 2026) | — | to be reported | — |
The latest quarter
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Questions
Does Regeneron Pharmaceuticals beat its guidance?
Regeneron Pharmaceuticals gave guidance in 2 earnings releases on file since Oct 30, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.